Scott Lauder

CTO at Gemini Therapeutics

Scott Lauder is our chief technology officer. Scott is a protein chemist with a deep background in biologics CMC development – from discovery through GMP manufacturing.

Prior to joining Gemini, Scott was vice president of process sciences and clinical manufacturing at Merrimack Pharmaceuticals and was global head of the protein and cell sciences group at EMD Serono. Scott has experience with a broad array of biologic formats including monoclonal Abs, recombinant proteins, as well as bispecifics and engineered fusion proteins, advancing many to clinical POC.

Scott received his undergraduate degree from the University of Manitoba and his doctorate from Northwestern University.


  • CTO

    Current role

View in org chart